Outset Medical
About: Outset Medical Inc is a medical technology company. It has developed a machine, Tablo, which reduces the cost and complexity of dialysis. Tablo provides Renal Replacement Therapy in Hospitals, Chronic Care in Dialysis Clinics and Home Dialysis.
Employees: 480
0
Funds holding %
of 7,139 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
118% more call options, than puts
Call options by funds: $159K | Put options by funds: $73K
33% more capital invested
Capital invested by funds: $17.6M [Q3] → $23.4M (+$5.73M) [Q4]
9% less funds holding
Funds holding: 80 [Q3] → 73 (-7) [Q4]
9.99% less ownership
Funds ownership: 50.05% [Q3] → 40.07% (-9.99%) [Q4]
29% less repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 24
35% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 17
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$3
243%
upside
Avg. target
$3
243%
upside
High target
$3
243%
upside
1 analyst rating
0 positive
0%
1 neutral
100%
0 negative
0%
RBC Capital Shagun Singh 63% 1-year accuracy 44 / 70 met price target | 243%upside $3 | Sector Perform Reiterated | 7 Jan 2025 |
Financial journalist opinion
Based on 8 articles about OM published over the past 30 days
Neutral
Seeking Alpha
2 days ago
Outset Medical, Inc. (OM) Q4 2024 Earnings Call Transcript
Outset Medical, Inc. (NASDAQ:OM ) Q4 2024 Earnings Conference Call February 19, 2025 5:00 PM ET Company Participants Jim Mazzola - Head of Investor Relations Leslie Trigg - Chair and CEO Nabeel Ahmed - Chief Financial Officer Conference Call Participants Marie Thibault - BTIG Shagun Singh - RBC Capital Markets Suraj Kalia - Oppenheimer Operator Good day, and thank you for standing by. Welcome to the Outset Medical Fourth Quarter 2024 Earnings Conference Call.
Positive
The Motley Fool
2 days ago
Outset Medical: Profitability Path Brightens
Outset Medical (OM 3.52%), the innovator behind the Tablo Hemodialysis System, reported fourth-quarter earnings on Wednesday, Feb. 19, that topped analysts' consensus expectations on top and bottom lines. Fourth-quarter revenue of $29.5 million exceeded the forecasted $28 million, indicating resilience in revenue growth despite market hurdles.
Negative
Zacks Investment Research
2 days ago
Outset Medical, Inc. (OM) Reports Q4 Loss, Tops Revenue Estimates
Outset Medical, Inc. (OM) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to loss of $0.59 per share a year ago.
Neutral
GlobeNewsWire
2 days ago
Outset Medical Reports Fourth Quarter and Full Year 2024 Financial Results
SAN JOSE, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported financial results for the fourth quarter and full year ended December 31, 2024.
Neutral
GlobeNewsWire
1 week ago
Outset Medical Announces Resolution of Warning Letter
SAN JOSE, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced it has been notified by the Food and Drug Administration that all issues cited in a Warning Letter the company received in July of 2023 have been addressed.
Negative
Zacks Investment Research
1 week ago
Outset Medical, Inc. (OM) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Outset Medical (OM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Neutral
GlobeNewsWire
2 weeks ago
Kuehn Law Encourages Investors of Outset Medical, Inc. to Contact Law Firm
NEW YORK, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Outset Medical, Inc. (NASDAQ: OM) breached their fiduciary duties to shareholders.
Neutral
GlobeNewsWire
2 weeks ago
Outset Medical to Report Fourth Quarter and Full-Year 2024 Financial Results on Wednesday, February 19, 2025
SAN JOSE, Calif., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that it will release financial results for the fourth quarter and full-year 2024 after the close of trading on Wednesday, February 19, 2025.
Neutral
GlobeNewsWire
1 month ago
Outset Medical Announces $169 Million Private Placement Financing From Leading Mutual Funds and Healthcare Institutional Investors
Secures New Debt Financing of up to $125M Maturing in 2030 with Plans to Retire $200M in Prior Debt
Neutral
GlobeNewsWire
2 months ago
OUTSET MEDICAL ALERT: Bragar Eagel & Squire, P.C. is Investigating Outset Medical, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
NEW YORK, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Outset Medical, Inc. (NASDAQ: OM) on behalf of long-term stockholders following a class action complaint that was filed against Outset Medical on August 29, 2024 with a Class Period from August 1, 2022 to August 7, 2024. Our investigation concerns whether the board of directors of Outset Medical have breached their fiduciary duties to the company.
Charts implemented using Lightweight Charts™